Read press release News
News provided by
in collaboration with
Please note that all copy is © Adfero LTD and does not reflect views or opinions of Cancer Research UK
unless explicitly stated
• About our news feed
Cancer News
US government approves prostate cancer treatment vaccine
Wednesday 5 May 2010
The US Food and Drug Administration (FDA) has approved a new 'cancer vaccine' for treating men with advanced prostate cancer.
Provenge (sipuleucel-T) has been approved for prostate cancer patients with few or no symptoms whose disease has spread to other parts of the body and who are not responding to hormone treatment.
It is a new type of treatment called immunotherapy, which stimulates the patient's own immune system to fight the cancer.
Immune cells are extracted from the patient's blood by a process called leukapheresis. The cells are then exposed to a protein found on prostate cancer cells to enhance their response against the cancer.
They are then returned to the patient via a drip, with three doses given at two-week intervals.
A trial involving 512 patients with advanced prostate cancer found that those who received Provenge typically survived for around four months longer than those who were not treated with the vaccine.
Side-effects such as chills, fatigue, fever, back pain and nausea were common, but tended to be mild.
Dr Karen Midthun, acting director of the FDA's Center for Biologics Evaluation and Research, said: "The availability of Provenge provides a new treatment option for men with advanced prostate cancer, who currently have limited effective therapies available."
Dr Chris Parker, a Cancer Research UK-funded prostate cancer expert at The Institute of Cancer Research, commented: "This is exciting news for the field of immunotherapy. It's the first time that any immunotherapy has been shown to increase survival for prostate cancer. Hopefully, this approval will open new avenues of research into using a patient's own immune system to treat cancer.
"The process for approving drugs in the UK is different from the US, so this treatment is not yet available here," he added.
- Share this: Tweet
-
-
- Print this page
-
Email this page
Visit our A-Z topic pages
Recent news and press releases
- Press Release: Non-Hodgkin lymphoma survival doubles since early 1970s (23 May 2013)
- Press Release: Beta-blockers may boost chemo effect in childhood cancer (22 May 2013)
- Press Release: Cancer survivors need more support to stop smoking and drinking (22 May 2013)
- News story: US scientists devise strategy to block key cancer molecule (21 May 2013)
- News story: New scheme to routinely test patients for inherited cancer genes (21 May 2013)
Increase text size
Decrease text size
Print page
“This is exciting news for the field of immunotherapy”
- Dr Chris Parker, Cancer Research UK
